Burgdorf – Ypsomed (SIX: YPSN) has completed the capital increase in the full amount of one million new shares very successfully. The subscription and placement price was set at CHF 122.50 after the expiry of the subscription and placement period, which ended on 23 June 2022 at 12:00 CEST. The issue price corresponds to the volume-weighted average price from 21 to 23 June 2022, until 12:00 noon, with a discount of 2.1%. The capital increase with a transaction volume of CHF 122.5 million met with great interest and was significantly oversubscribed. The new shares are eligible for the dividend payment of 06 July 2022. Zürcher Kantonalbank is the Sole Global Coordinator of this capital increase.
Rights offering and free placement
Within the subscription rights offering, 870’485 new shares were subscribed by existing shareholders. This corresponds to an above average exercise ratio of 89.5%. The remaining 129’515 new shares were sold very successfully in a free placement. The Board of Directors and the Executive Board would like to thank the shareholders and new investors for their trust. After the capital increase, Ypsomed Holding AG has a total of 13'649'739 registered shares with a nominal value of CHF 14.15 each, 73.7% of which are held by the Michel family shareholder group. The free float amounts to 26.3%. The first trading day of the new shares is scheduled for Tuesday, 28 June 2022.
Use of proceeds
By offsetting existing loans from Dr. h.c. Willy Michel against the company, it was possible to reduce the shareholder loans by CHF 85.0 million to CHF 25.0 million, thereby strengthening Ypsomed's balance sheet. The net proceeds from the capital increase thus amount to CHF 35.1 million. The funds accruing from the capital increase support the financing of the pre-investments in the accelerated production scale-up for injection systems and increase the financial flexibility to drive digitization forward.
Key data of the capital increase
|Stock exchange||SIX Swiss Exchange|
|Swiss security number||1939699|
|Subscription and placement price||CHF 122.50|
|Number of new shares||1'000'000 shares|
|Number of shares after capital increase||13'649'739 shares|
|Freefloat after capital increase||26.3%|
This media release and the information contained therein are not being issued in the United States of America, the United Kingdom or the European Economic Area and must not be distributed within or to such countries or via publications with a general circulation in such countries.
This media release serves informational purposes and constitutes neither an offer to sell nor a solicitation to buy any shares of YPSOMED HOLDING AG in any jurisdiction. This media release does not constitute a prospectus within the meaning of Article 35 et seqq. of the Swiss Federal Act on Financial Services. Investors should base their decision to purchase shares of YPSOMED HOLDING AG exclusively on the official prospectus. The shares described in the prospectus are publicly offered in Switzerland only. This media release is intended for the territory of Switzerland only. In addition, investors should seek advice from their bank or their financial adviser.
The information in this media release contains forward-looking statements and outlooks. Forward-looking statements and outlooks involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance, or achievements of YPSOMED HOLDING AG (including group companies), or industry results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements and outlooks. Given these risks, uncertainties and other factors, recipients of this media release are cautioned not to place undue reliance on these forward-looking statements and outlooks. YPSOMED HOLDING AG (including group companies), does not have any obligation to update these forward-looking statements and outlooks to reflect future events or developments. Past performance or any prediction or forecast is not necessarily indicative of future performance. No assurance is given that any objectives, targets, or predictions will be met. The information in this media release does not constitute investment advice or recommendation and was prepared without regard to the specific objectives, financial situation or needs of any particular person who may receive it.
In addition, certain information provided in this media release qualifies as advertisement within the meaning of Article 68 FinSA. Investment decisions should only be made after a thorough reading of the prospectus and/or prospectus supplement, and, if necessary, after obtaining advice from a financial, legal and tax advisor regarding the risks and rewards of an investment. The documents mentioned can be obtained free of charge from Zürcher Kantonalbank (e-mail: email@example.com; phone: +41 44 292 20 66).